Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00335556 · OUTCOME

Long-term Survival of Patients With Stage I-IV Malignant Rhabdoid Tumors

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors · Source last updated 2017-07-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of 4-year OS
Interval / dispersion
95% Confidence Interval
Time frame
4 years

What was measured

The outcome of these patients will be compared with a fixed outcome based on that seen for similar patients treated with NWTS-5 regimen (NCT00002610).

Analysis population: Eligible patients with Stage I-IV rhabdoid tumor.

Groups in this outcome

UH-1

Cyclophosphamide/carboplatin/etoposide; vincristine/doxorubicin/cyclophosphamide; x 30 weeks; XRT.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
UH-136

Reported measurements

Source class 1
Values in Percentage of 4-year OS · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
UH-138.9Not reported20.157.7Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    group Description
    The overall survival distributions of patients with Stage I-IV malignant rhabdoid tumors on AREN0321 and National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study (NCT00002610) were compared using the log-rank test.
    group Ids
    1. OG000
    non Inferiority Type
    OTHER
    p Value
    .3478
    param Type
    Log Rank Test Statistic
    param Value
    .8814
    statistical Method
    Log Rank
Complete source fields
analyses
  1. ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    group Description
    The overall survival distributions of patients with Stage I-IV malignant rhabdoid tumors on AREN0321 and National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study (NCT00002610) were compared using the log-rank test.
    group Ids
    1. OG000
    non Inferiority Type
    OTHER
    p Value
    .3478
    param Type
    Log Rank Test Statistic
    param Value
    .8814
    statistical Method
    Log Rank
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        20.1
        upper Limit
        57.7
        value
        38.9
denoms
  1. counts
    1. group Id
      OG000
      value
      36
    units
    Participants
description
The outcome of these patients will be compared with a fixed outcome based on that seen for similar patients treated with NWTS-5 regimen (NCT00002610).
dispersion Type
95% Confidence Interval
groups
  1. description
    Cyclophosphamide/carboplatin/etoposide; vincristine/doxorubicin/cyclophosphamide; x 30 weeks; XRT.
    id
    OG000
    title
    UH-1
param Type
NUMBER
population Description
Eligible patients with Stage I-IV rhabdoid tumor.
reporting Status
POSTED
time Frame
4 years
title
Long-term Survival of Patients With Stage I-IV Malignant Rhabdoid Tumors
type
PRIMARY
unit Of Measure
Percentage of 4-year OS

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice